Current use of vasopressors in septic shock

Abstract

BACKGROUND: Vasopressors are commonly applied to restore and maintain blood pressure in patients with sepsis. We aimed to evaluate the current practice and therapeutic goals regarding vasopressor use in septic shock as a basis for future studies and to provide some recommendations on their use. METHODS: From November 2016 to April 2017, an anonymous web-based survey on the use of vasoactive drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 17 questions focused on the profile of respondents, triggering factors, first choice agent, dosing, timing, targets, additional treatments, and effects of vasopressors. We investigated whether the answers complied with current guidelines. In addition, a group of 34 international ESICM experts was asked to formulate recommendations for the use of vasopressors based on 6 questions with sub-questions (total 14). RESULTS: A total of 839 physicians from 82 countries (65% main specialty/activity intensive care) responded. The main trigger for vasopressor use was an insufficient mean arterial pressure (MAP) response to initial fluid resuscitation (83%). The first-line vasopressor was norepinephrine (97%), targeting predominantly a MAP > 60-65 mmHg (70%), with higher targets in patients with chronic arterial hypertension (79%). The experts agreed on 10 recommendations, 9 of which were based on unanimous or strong (≥ 80%) agreement. They recommended not to delay vasopressor treatment until fluid resuscitation is completed but rather to start with norepinephrine early to achieve a target MAP of ≥ 65 mmHg. CONCLUSION: Reported vasopressor use in septic shock is compliant with contemporary guidelines. Future studies should focus on individualized treatment targets including earlier use of vasopressors.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 69

1. 1.

   Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, De Backer D, Payen D. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006;34(3):589-597.

   Not in our library10.1097/01.ccm.0000201896.45809.e3

2. 2.

   Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mebazaa A, Pinsky MR, Teboul JL, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795-1815.

   Not in our library10.1007/s00134-014-3525-z

3. 3.

   Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-1734.

   Not in our library10.1056/nejmra1208943

4. 4.

   Weil MH. Personal commentary on the diagnosis and treatment of circulatory shock states. Curr Opin Crit Care. 2004;10(4):246-249.

   Not in our library10.1097/01.ccx.0000135265.30310.77

5. 5.

   Hiemstra B, Eck RJ, Keus F, van der Horst ICC. Clinical examination for diagnosing circulatory shock. Curr Opin Crit Care. 2017;23(4):293-301.

   Not in our library10.1097/mcc.0000000000000420

6. 6.

   De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

   Not in our library10.1056/nejmoa0907118

7. 7.

   Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228.

   Not in our library10.1007/s00134-012-2769-8

8. 8.

   Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock—2016. Intensive Care Med. 2017;43(3):304-377.

   Not in our library10.1007/s00134-017-4683-6

9. 9.

   Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44(6):925-928.

   Not in our library10.1007/s00134-018-5085-0

10. 10.

    Asfar P, Teboul JL, Radermacher P. High versus low blood-pressure target in septic shock. N Engl J Med. 2014;371(3):283-284.

    Not in our library10.1056/nejmc1406276

11. 11.

    Lamontagne F, Day AG, Meade MO, Cook DJ, Guyatt GH, Hylands M, Radermacher P, Chretien JM, Beaudoin N, Hebert P, et al. Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock. Intensive Care Med. 2018;44(1):12-21.

    Not in our library10.1007/s00134-017-5016-5

12. 12.

    Hamzaoui O, Scheeren TWL, Teboul JL. Norepinephrine in septic shock: when and how much? Curr Opin Crit Care. 2017;23(4):342-347.

    Not in our library10.1097/mcc.0000000000000418

13. 13.

    McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, Lamontagne F, Healey JS, Whitlock RP, Belley-Cote EP. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA. 2018;319(18):1889-1900.

    Not in our library10.1001/jama.2018.4528

14. 14.

    Lesur O, Delile E, Asfar P, Radermacher P. Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care. 2018;8(1):102.

    Not in our library10.1186/s13613-018-0449-8

15. 15.

    Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810.

    Not in our library10.1001/jama.2016.0287

16. 16.

    Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392(10141):75-87.

    Not in our library10.1016/s0140-6736(18)30696-2

17. 17.
    Definitions and pathophysiology of vasoplegic shock · 2018

    No notice
18. 18.

    Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.

    Not in our library10.2196/jmir.6.3.e34

19. 19.

    Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, van het Loo M, McDonnell J, Vader JP, Kahan JP. The RAND/UCLA appropriateness method user’s manual. RAND Corporation; 2001.

    Not in our library

20. 20.

    Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of refractory vasodilatory shock. Chest. 2018;154(2):416-426.

    Not in our library10.1016/j.chest.2017.12.021

21. 21.

    Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797-808.

    Not in our library10.1056/nejmoa1705835

22. 22.

    Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809-818.

    Not in our library10.1056/nejmoa1705716

23. 23.

    World Bank: World bank country and lending groups. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 18 Jan 2019.

    Not in our library

24. 24.

    Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583-1593.

    Not in our library10.1056/nejmoa1312173

25. 25.

    Lamontagne F, Meade MO, Hebert PC, Asfar P, Lauzier F, Seely AJE, Day AG, Mehta S, Muscedere J, Bagshaw SM, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med. 2016;42(4):542-550.

    Not in our library10.1007/s00134-016-4237-3

26. 26.

    Maheshwari K, Nathanson BH, Munson SH, Khangulov V, Stevens M, Badani H, Khanna AK, Sessler DI. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018;44:857-867.

    Not in our library10.1007/s00134-018-5218-5

27. 27.

    Cecconi M, Hofer C, Teboul JL, Pettila V, Wilkman E, Molnar Z, Della Rocca G, Aldecoa C, Artigas A, Jog S, et al. Fluid challenges in intensive care: the FENICE study: a global inception cohort study. Intensive Care Med. 2015;41(9):1529-1537.

    Not in our library10.1007/s00134-015-3850-x

28. 28.

    Funcke S, Sander M, Goepfert MS, Groesdonk H, Heringlake M, Hirsch J, Kluge S, Krenn C, Maggiorini M, Meybohm P, et al. Practice of hemodynamic monitoring and management in German, Austrian, and Swiss intensive care units: the multicenter cross-sectional ICU-CardioMan Study. Ann Intensive Care. 2016;6(1):49.

    Not in our library10.1186/s13613-016-0148-2

29. 29.

    Le Dorze M, Huche F, Coelembier C, Rabuel C, Payen D. Impact of fluid challenge increase in cardiac output on the relationship between systemic and cerebral hemodynamics in severe sepsis compared to brain injury and controls. Ann Intensive Care. 2018;8(1):74.

    Not in our library10.1186/s13613-018-0419-1

30. 30.

    Lamontagne F, Cook DJ, Meade MO, Seely A, Day AG, Charbonney E, Serri K, Skrobik Y, Hebert P, St-Arnaud C, et al. Vasopressor use for severe hypotension: a multicentre prospective observational study. PLoS ONE. 2017;12(1):e0167840.

    Not in our library10.1371/journal.pone.0167840

31. 31.

    Hernandez G, Cavalcanti AB, Ospina-Tascon G, Zampieri FG, Dubin A, Hurtado FJ, Friedman G, Castro R, Alegria L, Cecconi M, et al. Early goal-directed therapy using a physiological holistic view: the ANDROMEDA-SHOCK—a randomized controlled trial. Ann Intensive Care. 2018;8(1):52.

    Not in our library10.1186/s13613-018-0398-2

32. 32.

    Kollind M, Wickbom F, Wilkman E, Snackestrand MS, Holmen A, Oldner A, Perner A, Aneman A, Chew MS. Scandinavian Critical Care Trials G: shock treatment in a cohort of Scandinavian intensive care units in 2014. Acta Anaesthesiol Scand. 2016;60(7):945-957.

    Not in our library10.1111/aas.12745

33. 33.

    Lamontagne F, Cook DJ, Adhikari NKJ, Briel M, Duffett M, Kho ME, Burns KEA, Guyatt G, Turgeon AF, Zhou Q, et al. Vasopressor administration and sepsis: a survey of Canadian intensivists. J Crit Care. 2011;26(5):532e531-532e537.

    Not in our library10.1016/j.jcrc.2011.01.005

34. 34.

    Oldner A, Rossi P, Karason S, Aneman A. Scandinavian Critical Care Trials G: a practice survey on vasopressor and inotropic drug therapy in Scandinavian intensive care units. Acta Anaesthesiol Scand. 2003;47(6):693-701.

    Not in our library10.1034/j.1399-6576.2003.00129.x

35. 35.

    De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med. 2012;40(3):725-730.

    Not in our library10.1097/ccm.0b013e31823778ee

36. 36.
    Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis · 2015

    No notice
37. 37.

    Hiemstra B, Koster G, Wetterslev J, Gluud C, Jakobsen JC, Scheeren TWL, Keus F, van der Horst ICC. Dopamine in critically ill patients with cardiac dysfunction: A systematic review with meta-analysis and trial sequential analysis. Acta Anaesthesiol Scand. 2018.

    Not in our library10.1111/aas.13294

38. 38.

    Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA. 2017;317(14):1433-1442.

    Not in our library10.1001/jama.2017.2841

39. 39.

    Donohue JM, Angus DC. National shortages of generic sterile injectable drugs: norepinephrine as a case study of potential harm. JAMA. 2017;317(14):1415-1417.

    Not in our library10.1001/jama.2017.2826

40. 40.

    Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509-518.

    Not in our library10.1001/jama.2016.10485

Cited by papers we hold 2

• Modified cardiovascular SOFA score in sepsis: development and internal and external validation · 2022
  Not checked
• Management of sepsis and septic shock in the emergency department · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.